[ET Net News Agency, 25 May 2021] Macquarie lowered its target price for Junshi Bio
(01877) to HK$87.74 and maintained its "outperform" rating.
The research house said despite recent approval of the combination of Junshi's COVID
antibody (etesevimab) and bamlanivimab in Brazil, it is more conservative towards future
demand of Junshi's antibody due to a rise of mutants. (RC)